使用小剂量安罗替尼和免疫检查点抑制剂联合治疗广泛期小细胞肺癌。

Cancer Innovation Pub Date : 2024-10-28 DOI:10.1002/cai2.155
Han Li, Shumin Yuan, Han Wu, Yajie Wang, Yichen Ma, Xiance Tang, Xiaomin Fu, Lingdi Zhao, Benling Xu, Tiepeng Li, Peng Qin, Hongqin You, Lu Han, Zibing Wang
{"title":"使用小剂量安罗替尼和免疫检查点抑制剂联合治疗广泛期小细胞肺癌。","authors":"Han Li,&nbsp;Shumin Yuan,&nbsp;Han Wu,&nbsp;Yajie Wang,&nbsp;Yichen Ma,&nbsp;Xiance Tang,&nbsp;Xiaomin Fu,&nbsp;Lingdi Zhao,&nbsp;Benling Xu,&nbsp;Tiepeng Li,&nbsp;Peng Qin,&nbsp;Hongqin You,&nbsp;Lu Han,&nbsp;Zibing Wang","doi":"10.1002/cai2.155","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>This study evaluated the efficacy and safety of low-dose anlotinib combined with immune checkpoint inhibitors as second-line or later treatment for extensive-stage small cell lung cancer (ES-SCLC).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The study included 42 patients with ES-SCLC who were treated with low-dose anlotinib combined with programmed cell death protein 1/programmed cell death-ligand 1 inhibitors at Henan Cancer Hospital between March 2019 and August 2022. We retrospectively analyzed the efficacy and safety data for these patients. Indicators assessed included progression-free survival (PFS), overall survival (OS), the overall response rate (ORR), the disease control rate (DCR), and adverse events (AEs). Prognostic factors were identified in univariate and multivariate analyses.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Median PFS was 11.0 months (95% CI: 7.868–14.132) and median OS was 17.3 months (95% CI: 11.517–23.083). The ORR was 28.5% and the DCR was 95.2%. Treatment-related AEs were noted in 27 patients (64.3%), the most common of which was thyroid dysfunction (26.2%). Grade 3/4 treatment-related AEs were observed in two patients (4.8%).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>A combination of low-dose anlotinib and immune checkpoint inhibitors as second-line or later treatment for ES-SCLC may achieve longer PFS and OS and have manageable AEs.</p>\n </section>\n </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"3 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11516071/pdf/","citationCount":"0","resultStr":"{\"title\":\"Combination therapy using low-dose anlotinib and immune checkpoint inhibitors for extensive-stage small cell lung cancer\",\"authors\":\"Han Li,&nbsp;Shumin Yuan,&nbsp;Han Wu,&nbsp;Yajie Wang,&nbsp;Yichen Ma,&nbsp;Xiance Tang,&nbsp;Xiaomin Fu,&nbsp;Lingdi Zhao,&nbsp;Benling Xu,&nbsp;Tiepeng Li,&nbsp;Peng Qin,&nbsp;Hongqin You,&nbsp;Lu Han,&nbsp;Zibing Wang\",\"doi\":\"10.1002/cai2.155\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>This study evaluated the efficacy and safety of low-dose anlotinib combined with immune checkpoint inhibitors as second-line or later treatment for extensive-stage small cell lung cancer (ES-SCLC).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>The study included 42 patients with ES-SCLC who were treated with low-dose anlotinib combined with programmed cell death protein 1/programmed cell death-ligand 1 inhibitors at Henan Cancer Hospital between March 2019 and August 2022. We retrospectively analyzed the efficacy and safety data for these patients. Indicators assessed included progression-free survival (PFS), overall survival (OS), the overall response rate (ORR), the disease control rate (DCR), and adverse events (AEs). Prognostic factors were identified in univariate and multivariate analyses.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Median PFS was 11.0 months (95% CI: 7.868–14.132) and median OS was 17.3 months (95% CI: 11.517–23.083). The ORR was 28.5% and the DCR was 95.2%. Treatment-related AEs were noted in 27 patients (64.3%), the most common of which was thyroid dysfunction (26.2%). Grade 3/4 treatment-related AEs were observed in two patients (4.8%).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>A combination of low-dose anlotinib and immune checkpoint inhibitors as second-line or later treatment for ES-SCLC may achieve longer PFS and OS and have manageable AEs.</p>\\n </section>\\n </div>\",\"PeriodicalId\":100212,\"journal\":{\"name\":\"Cancer Innovation\",\"volume\":\"3 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11516071/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Innovation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cai2.155\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Innovation","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cai2.155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

研究背景本研究评估了小剂量安罗替尼联合免疫检查点抑制剂作为广泛期小细胞肺癌(ES-SCLC)二线或后期治疗的有效性和安全性:研究纳入了2019年3月至2022年8月在河南省肿瘤医院接受低剂量安罗替尼联合程序性细胞死亡蛋白1/程序性细胞死亡配体1抑制剂治疗的42例ES-SCLC患者。我们对这些患者的疗效和安全性数据进行了回顾性分析。评估指标包括无进展生存期(PFS)、总生存期(OS)、总反应率(ORR)、疾病控制率(DCR)和不良事件(AEs)。单变量和多变量分析确定了预后因素:中位 PFS 为 11.0 个月(95% CI:7.868-14.132),中位 OS 为 17.3 个月(95% CI:11.517-23.083)。ORR为28.5%,DCR为95.2%。27名患者(64.3%)出现了治疗相关的AEs,其中最常见的是甲状腺功能障碍(26.2%)。2名患者(4.8%)出现了3/4级治疗相关不良反应:结论:小剂量安罗替尼和免疫检查点抑制剂联合作为ES-SCLC的二线或后期治疗,可获得更长的PFS和OS,且AEs可控。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Combination therapy using low-dose anlotinib and immune checkpoint inhibitors for extensive-stage small cell lung cancer

Background

This study evaluated the efficacy and safety of low-dose anlotinib combined with immune checkpoint inhibitors as second-line or later treatment for extensive-stage small cell lung cancer (ES-SCLC).

Methods

The study included 42 patients with ES-SCLC who were treated with low-dose anlotinib combined with programmed cell death protein 1/programmed cell death-ligand 1 inhibitors at Henan Cancer Hospital between March 2019 and August 2022. We retrospectively analyzed the efficacy and safety data for these patients. Indicators assessed included progression-free survival (PFS), overall survival (OS), the overall response rate (ORR), the disease control rate (DCR), and adverse events (AEs). Prognostic factors were identified in univariate and multivariate analyses.

Results

Median PFS was 11.0 months (95% CI: 7.868–14.132) and median OS was 17.3 months (95% CI: 11.517–23.083). The ORR was 28.5% and the DCR was 95.2%. Treatment-related AEs were noted in 27 patients (64.3%), the most common of which was thyroid dysfunction (26.2%). Grade 3/4 treatment-related AEs were observed in two patients (4.8%).

Conclusions

A combination of low-dose anlotinib and immune checkpoint inhibitors as second-line or later treatment for ES-SCLC may achieve longer PFS and OS and have manageable AEs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
0
期刊最新文献
lncRNA TCONS_00251376 promotes the proliferation and migration of gastric cancer cell through upregulating ETV1 Expression pattern and prognostic significance of aldehyde dehydrogenase 2 in lung adenocarcinoma as a potential predictor of immunotherapy efficacy Subtype-specific transcription factors affect polyamine metabolism and the tumor microenvironment in breast cancer Effectiveness of ultrasound-guided vacuum-assisted excision for treating benign breast lesions Mitigating ibrutinib-induced ventricular arrhythmia and cardiac dysfunction with metformin
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1